- Trials with a EudraCT protocol (116)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
116 result(s) found for: Overactive Bladder.
Displaying page 6 of 6.
EudraCT Number: 2010-020220-22 | Sponsor Protocol Number: H6D-MC-LVIR | Start Date*: 2010-12-21 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men with Signs and Symptoms of Be... | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005295-33 | Sponsor Protocol Number: S54913 | Start Date*: 2013-03-08 | |||||||||||
Sponsor Name:UZ Leuven-Department of Urology | |||||||||||||
Full Title: Monocentric, open-label, phase III study that compares the efficiency and tolerance between intravesical oxybutynin and oral fesoterodine in children (5-16y) with neurogenic detrusor overactivity. | |||||||||||||
Medical condition: children with neurogenic detrusor overactivity | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005431-97 | Sponsor Protocol Number: B3P104833 | Start Date*: 2006-03-14 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: An Eight-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Dose Ranging Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile... | ||
Medical condition: Overactive bladder (OAB) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FI (Completed) DE (Completed) SI (Completed) LV (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002894-21 | Sponsor Protocol Number: CDAR328A2409 | Start Date*: 2005-06-21 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration... | ||
Medical condition: Overactive bladder (OAB) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Completed) HU (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005868-93 | Sponsor Protocol Number: AV608-106 | Start Date*: 2006-05-15 |
Sponsor Name:AVERA PHARMACEUTICALS INC. | ||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects with Idiopathic Detrusor Overactivity | ||
Medical condition: Idiopathic Detrusor Overactivity (Overactive Bladder) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004296-22 | Sponsor Protocol Number: 2014-RdC-PRO-Th | Start Date*: 2015-11-10 | |||||||||||
Sponsor Name:Centre Eugène Marquis | |||||||||||||
Full Title: Anticholinergics impact in the treatment of acute irritative urinary toxicity during radiotherapy for prostate cancer | |||||||||||||
Medical condition: Symptomatology related to acute urinary toxicity occuring during prostate irradiation in patients suffering from prostate cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000250-28 | Sponsor Protocol Number: 905-CL-079 | Start Date*: 2011-11-15 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with... | |||||||||||||
Medical condition: Neurogenic Detrusor Overactivity (NDO) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002277-38 | Sponsor Protocol Number: KMD3213ITCL0477 | Start Date*: 2015-07-30 | |||||||||||
Sponsor Name:RECORDATI S.P.A. | |||||||||||||
Full Title: Urodynamic evaluation by pressure flow urodynamic study of the new α1A-adrenoceptor antagonist silodosin 8 mg qd in patients with benign prostatic obstruction. Explorative, single-arm, phase IV cli... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003178-22 | Sponsor Protocol Number: 905-CL-074 | Start Date*: 2013-04-17 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose -Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Child... | |||||||||||||
Medical condition: Neurogenic Detrusor Overactivity (NDO) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) BE (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002841-21 | Sponsor Protocol Number: H6D-MC-LVHJ(a) | Start Date*: 2008-10-28 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of B... | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010739-42 | Sponsor Protocol Number: H6D-MC-LVID | Start Date*: 2009-10-01 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs ... | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) BE (Completed) AT (Completed) IT (Completed) FR (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023210-31 | Sponsor Protocol Number: Y52-52120-155 | Start Date*: 2012-02-24 | |||||||||||
Sponsor Name:Ipsen Innovation | |||||||||||||
Full Title: A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNIT... | |||||||||||||
Medical condition: NEUROGENIC DETRUSOR OVERACTIVITY | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) IT (Completed) LT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000259-35 | Sponsor Protocol Number: 2020_03 | Start Date*: 2022-04-29 | |||||||||||
Sponsor Name:Centre Hospitalier Universitaire de Lille | |||||||||||||
Full Title: Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections | |||||||||||||
Medical condition: Overactive bladder (OAB) and/or detrusor overactivity (DO) in multiple sclerosis (MS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016800-22 | Sponsor Protocol Number: I1A-MC-BPAE | Start Date*: 2010-05-14 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (B... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006656-35 | Sponsor Protocol Number: A3711047 | Start Date*: 2007-06-12 | |||||||||||
Sponsor Name:Pfizer Ltd | |||||||||||||
Full Title: A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage L... | |||||||||||||
Medical condition: Storage male lower urinary tract symptoms (LUTS) with and without erectile dysfunction (ED). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) FI (Completed) DE (Completed) GB (Completed) GR (Completed) LV (Completed) IT (Completed) SK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002451-41 | Sponsor Protocol Number: NX1207-IT-CL0414 | Start Date*: 2013-08-21 | |||||||||||
Sponsor Name:Recordati S.p.A. | |||||||||||||
Full Title: EFFICACY AND SAFETY OF A SINGLE TRUS-GUIDED INTRAPROSTATIC INJECTION OF NX-1207 IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA: A PHASE III EUROPEAN CLI... | |||||||||||||
Medical condition: LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) PT (Prematurely Ended) ES (Prematurely Ended) GB (Completed) IT (Prematurely Ended) PL (Completed) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
